← Back to all signals
RESEARCH PAPER ANALYSIS

Correlations Between Clinical, Anthropometric and Nutritional Evaluations in Patients with Parkinson's Disease from Ghana: A Cross-Sectional Study.

Small cross-sectional study of 20 Ghanaian PD patients found high rates of malnutrition (≈75%), sarcopenia (45%) and constipation (80%), low caloric/protein intake linked to lower BMI/body fat, thigh circumference inversely correlated with disease duration, and protein intake inversely correlated…

PMID41976987
JournalJournal of clinical medicine
Publication Date2026-04-02
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Small cross-sectional study of 20 Ghanaian PD patients found high rates of malnutrition (≈75%), sarcopenia (45%) and constipation (80%), low caloric/protein intake linked to lower BMI/body fat, thigh circumference inversely correlated with disease duration, and protein intake inversely correlated…

WHY IT MATTERS

Research significance

Identifies modifiable nutritional deficits and sarcopenia as actionable targets for symptomatic management and multidisciplinary interventions in PD—especially in resource-limited settings—though the small sample and lack of mechanistic data limit direct therapeutic-discovery impact.

ABSTRACT

Source abstract

Introduction: Malnutrition and sarcopenia are commonly observed in African patients with Parkinson's disease (PD); however, limited data exist regarding the nutritional status and body composition of PD patients in sub-Saharan Africa. This study aims to describe the clinical, nutritional, and anthropometric characteristics of PD patients from Sogakope, in the Volta Region of Ghana. Methods: A total of 20 PD patients were recruited. All participants underwent comprehensive clinical and nutritional assessments. Motor symptoms were evaluated with the Unified Parkinson's Disease Rating Scale (UPDRS). Dealing with non-motor symptoms, constipation was diagnosed according to the Roma III Criteria while dysphagia was assessed using the Swallowing Disturbance Questionnaire. The presence and impact of sialorrhea was determined using the Sialorrhea Clinical Scale. Nutritional assessment was performed with the Mini Nutritional Assessment short form (MNA-sf). Body composition parameters were measured using Bioelectrical Impedance Analysis (BIA), and muscle strength was evaluated with the Handgrip Strength Test. Correlations were assessed by Pearson or Spearman correlation analysis, as appropriate. Partial correlation analysis controlling for significant clinical variables was also performed. Results: Daily caloric intake was significantly lower compared to Western populations and was associated with a reduced body mass index (BMI) and body fat percentage. Constipation (80%) and sarcopenia (45%) were highly prevalent, whereas dysphagia was reported in only 15% of participants. Over 75% of patients were at risk of malnutrition. A significant inverse correlation was found between thigh circumference and disease duration (r = -0.517; p = 0.02). Additionally, protein intake (g/kg/day) was inversely correlated with motor symptom severity, as measured by the UPDRS Part III in the ON state (r = -0.544; p = 0.02). Conclusions: This study demonstrates a high prevalence of nutritional deficiencies, sarcopenia, and altered body composition in Ghanaian PD patients. These nutritional impairments are significantly associated with disease duration and motor symptom severity. The findings highlight the urgent need for early nutritional screening and intervention as part of a multidisciplinary approach to Parkinson's disease management in resource-limited settings.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic